Core Viewpoint - Nanwei Technology's stock has shown significant growth this year, with a 60.18% increase, indicating strong market performance and investor interest [1]. Group 1: Stock Performance - As of August 22, Nanwei Technology's stock price reached 28.09 CNY per share, with a market capitalization of 11.343 billion CNY [1]. - The stock has experienced a 3.27% increase over the last five trading days, a 2.41% increase over the last 20 days, and a 33.91% increase over the last 60 days [1]. - Year-to-date, the stock has appeared on the trading leaderboard once, with a net buy of -5.5156 million CNY on February 27 [1]. Group 2: Financial Performance - For the period from January to March 2025, Nanwei Technology reported a revenue of 189 million CNY, reflecting a year-on-year growth of 22.39% [2]. - The company has distributed a total of 115 million CNY in dividends since its A-share listing, with 86.8418 million CNY distributed over the past three years [2]. Group 3: Shareholder Information - As of March 31, 2025, the number of shareholders for Nanwei Technology was 14,800, a decrease of 0.99% from the previous period [2]. - The average number of circulating shares per shareholder increased by 1.00% to 27,351 shares [2]. - Among the top ten circulating shareholders, the China Europe Medical Health Mixed A fund is a new entrant, holding 8.6703 million shares [2].

问：介绍一下公司签约战略客户的考虑以及实施战略客户营销策略给公司带来了什么影响？ 证券之星消息，2025年8月6日纳微科技(688690)发布公告称华泰证券、华夏基金、开心龙基金、常州投资集团于2025 年8月5日调研我司。 具体内容如下： 纳微科技(688690)主营业务：公司是一家专门从事高性能纳米微球材料研发、规模化生产、销售及应用服务,为生物医 药、平板显示、分析检测及体外诊断等领域客户提供核心微球材料及相关技术解决方案的高新技术企业。公司自设立 以来,专注于高性能纳米微球的制备和应用技术研究,致力于成为全球领先的微球品牌,打造战略性新兴产业的中 国"芯"材料。 纳微科技2025年一季报显示，公司主营收入1.89亿元，同比上升22.39%；归母净利润2921.54万元，同比上升 72.98%；扣非净利润2507.61万元，同比上升85.28%；负债率15.46%，投资收益-3.36万元，财务费用16.81万元，毛利 率72.77%。 该股最近90天内共有3家机构给出评级，买入评级2家，增持评级1家。 以下是详细的盈利预测信息： 答：公司坚决执行"以客户为中心，以市场为导向"的营销策略，通过公司高层与战 ...